title: Antimetastatic and antitumor effect of a recombinant human tissue inhibitor of metalloproteinases-2 in murine melanoma models.
abstract: Tumor metastasis into distinct organs and tissues, of which many patients with malignancies die, is regulated in multiple steps. Using a murine metastasis model, in which highly metastatic B16-BL6 melanoma cells were inoculated i.v. into syngeneic C57BL/6 mice, the administration of a recombinant human tissue inhibitor of metalloproteinases-2 (r-hTIMP-2) once a day on days -1 to 3 after the implantation significantly inhibited the formation of metastatic foci in the lungs. The antimetastatic effect of r-hTIMP-2 was detected irrespective of administration route [i.v., i.p., s.c., and i.m. routes] and in a dose-dependent manner. The i.m.-injection of r-hTIMP-2 during the early phase after tumor inoculation is suggested to be essential for antimetastasis. In another model using spontaneously metastasing B16-BL6 cells, multiple i.m.-injections of r-hTIMP-2 also resulted in a reduced but not statistically significant number of pulmonary metastases. In addition to these antimetastatic effects, a slight inhibitory effect on tumor cell growth was observed in vitro and in vivo. In conclusion, the antimetastasis by r-hTIMP-2 may be due to inhibition of the degradation of the extracellular matrix by matrix metalloproteinases (MMPs) and, in part, to the suppression of the tumor cell growth.
authors.affiliation: Biopharmaceutical Department, Fuji Chemical Industries, Ltd., Toyama, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Oku
authors.forename: N
authors.initials: N
authors.lastname: Ata
authors.forename: K
authors.initials: K
authors.lastname: Yonezawa
authors.forename: H
authors.initials: H
authors.lastname: Tokai
authors.forename: H
authors.initials: H
authors.lastname: Fujii
authors.forename: A
authors.initials: A
authors.lastname: Shinagawa
authors.forename: E
authors.initials: E
authors.lastname: Ohuchi
authors.forename: I
authors.initials: I
authors.lastname: Saiki
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000494:pharmacology*; D002465:Cell Movement / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000493:pharmacokinetics / Q000494:pharmacology*; D005780:Gelatin / Q000737:chemistry; D006801:Humans; D007263:Infusions, Parenteral; D008546:Melanoma, Experimental / Q000188:drug therapy*; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors*; D051379:Mice; D009362:Neoplasm Metastasis / Q000517:prevention & control*; D011480:Protease Inhibitors / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D011480:Protease Inhibitors; D005780:Gelatin; D008666:Metalloendopeptidases